Urogen Pharma (DE:UR8)
NASDAQ:UR8
UR8 Stock Chart & Stats
€17.74
€0.00(0.00%)
At close: 4:00 PM EST
€17.74
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€10.70 - €28.99
Previous CloseN/A
Volume0.00
Average Volume (3M)4.00
Market Cap
€1.47B
Enterprise Value€1.68B
Total Cash (Recent Filing)€141.60M
Total Debt (Recent Filing)€197.09M
Price to Earnings (P/E)―
Beta-0.65
Next Earnings
Aug 06, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.75
Shares Outstanding48,721,703
10 Day Avg. Volume6
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)-10.68
Price to Sales (P/S)10.26
P/FCF Ratio-6.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€32.05Price Target Upside80.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.8
Revenue Forecast (FY)€231.81M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & High Gross MarginsSustained top-line growth from $48M (2021) to $140.5M TTM, paired with very high gross margins (~88–90%), creates a durable gross-profit base. This margin profile supports reinvestment into commercialization and R&D and increases the likelihood that scale will eventually translate into improved operating leverage.
ZUSDURI Early Commercial TractionRapid prescriber adoption and growing repeat use signal durable product-market fit in a specialized channel. Improving conversion times and a shift toward community settings expand addressable reach and indicate that the launch is progressing from awareness to sustained utilization, underpinning multi-quarter revenue durability.
Robust Pipeline With Near-term CatalystsA pipeline delivering near-term regulatory milestones diversifies future revenue streams beyond current products. Successful approvals would materially reduce single-product risk, add commercial optionality, and extend the company's long-term growth runway, making its fundamentals less dependent on one launch's trajectory.
Bears Say
Weak Balance Sheet & Rising LeverageNegative shareholder equity combined with materially higher debt constrains financial flexibility and increases refinancing and covenant risk. This structural leverage reduces the company's ability to fund growth organically, heightens interest expense sensitivity, and elevates dilution or restructuring risk over the next several quarters.
Persistent Cash Burn & Negative Free Cash FlowSustained large negative operating and free cash flows require ongoing external financing and limit runway. Persistent cash burn forces prioritization of projects, increases dependency on debt/equity raises, and raises execution risk for commercialization and pivotal trials across the 2–6 month horizon.
Unprofitability And Elevated Launch SG&AHigh launch-related selling, general and administrative costs sustain sizable operating losses despite revenue growth. Until unit economics improve and prescriber penetration scales materially, elevated SG&A will depress margins and cash flow, prolonging the path to sustainable profitability and increasing financing needs.
Urogen Pharma News
UR8 FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest stock price was €10.70 and its highest was €28.99 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is €1.47B.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Aug 06, 2026 which is in 41 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on May 06, 2026. The company reported -€0.403 earnings per share for the quarter, beating the consensus estimate of -€0.413 by €0.01.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is -0.26.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 48,721,703 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -€0.403 in its last earnings report, beating expectations of -€0.413. Following the earnings report the stock price went up 1.874%.
Which hedge fund is a major shareholder of Urogen Pharma?
Currently, no hedge funds are holding shares in DE:UR8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Urogen Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€32.05 (80.66% Upside)
€32.05 (80.66% Upside)
Blogger Sentiment
Bullish
DE:UR8 Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
150.58%
12-Months-Change
Fundamentals
Return on Equity
121.52%
Trailing 12-Months
Asset Growth
2.45%
Trailing 12-Months
Company Description
Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
UR8 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong early commercial traction for ZUSDURI with robust revenue growth, improving prescriber metrics, better conversion timelines, and a solid pipeline with near-term regulatory milestones. These positives are tempered by elevated SG&A related to the launch, ongoing net losses, limited current prescriber penetration relative to long-term targets, and continued uncertainty around full-year ZUSDURI revenue. On balance, the company is demonstrating accelerating commercial momentum and advancement of programs while managing costs and liquidity.View all DE:UR8 earnings summariesUR8 Stock 12 Month Forecast
Average Price Target
€32.05
▲(80.66% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Phathom Pharmaceuticals
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Options Prices
Currently, No data available
---